Such a PPARγ-regulating mechanism, ligand-dependent transrepression of transcription factors, has been described in the case of immune cells [41], and would open the door to the repurposing of type II diabetes mellitus drugs for their use in epilepsy. Here, PPARG is linked to type 2 diabetes mellitus.